Anavex Life Sciences (NASDAQ:AVXL) Shares Pass Below 50 Day Moving Average – Time to Sell?

Anavex Life Sciences Corp. (NASDAQ:AVXL)’s share price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.89 and traded as low as $2.56. Anavex Life Sciences shares last traded at $2.59, with a volume of 892,938 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Rodman & Renshaw initiated coverage on Anavex Life Sciences in a research report on Monday, May 4th. They set a “buy” rating and a $20.00 target price for the company. Weiss Ratings cut shares of Anavex Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Finally, D. Boral Capital reissued a “buy” rating and issued a $24.00 target price on shares of Anavex Life Sciences in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Anavex Life Sciences has an average rating of “Hold” and a consensus price target of $21.33.

Anavex Life Sciences Price Performance

The company has a market cap of $255.77 million, a P/E ratio of -6.00 and a beta of 1.14. The firm’s 50-day moving average is $2.85 and its two-hundred day moving average is $3.64.

Institutional Trading of Anavex Life Sciences

A number of large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Anavex Life Sciences by 10.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,525 shares of the biotechnology company’s stock valued at $434,000 after buying an additional 4,869 shares in the last quarter. Legal & General Group Plc grew its position in Anavex Life Sciences by 19.0% in the second quarter. Legal & General Group Plc now owns 86,972 shares of the biotechnology company’s stock worth $802,000 after acquiring an additional 13,886 shares in the last quarter. Rhumbline Advisers grew its position in Anavex Life Sciences by 6.1% in the second quarter. Rhumbline Advisers now owns 128,370 shares of the biotechnology company’s stock worth $1,184,000 after acquiring an additional 7,377 shares in the last quarter. American Century Companies Inc. bought a new stake in Anavex Life Sciences during the second quarter worth approximately $135,000. Finally, Prudential Financial Inc. bought a new stake in Anavex Life Sciences during the second quarter worth approximately $95,000. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.